Atherogenic dyslipidemia of 3.4% in our patients signifies an increase in apolipoprotein B (ApoB), and a shift of LDL pool towards small, dense LDL that are cholesterol-ester depleted, and more atherogenic with higher risk for ASCVD [45,46]. This evidence concerns the gene APOB and metabolic syndrome.